Foscarbidopa/foslevodopa: Difference between revisions
Content deleted Content added
update infobox |
Entranced98 (talk | contribs) Importing Wikidata short description: "Combination drug" |
||
| Line 1: | Line 1: | ||
{{Short description|Combination drug}} |
|||
{{Orphan|date=November 2023}} |
{{Orphan|date=November 2023}} |
||
{{Infobox drug |
{{Infobox drug |
||
Revision as of 14:11, 3 March 2024
 Chemical structure of foscarbidopa | |
 Chemical structure of foslevodopa | |
| Combination of | |
|---|---|
| Foscarbidopa | Prodrug of carbidopa |
| Foslevodopa | Prodrug of levodopa |
| Clinical data | |
| Trade names | Vyalev |
| Other names | ABBV-951 |
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status | |
Foscarbidopa/foslevodopa is a combination of prodrugs for levodopa and carbidopa that is developed by AbbVie to treat Parkinson's disease.[3][4][5][6][7] The combination was refused FDA approval in early 2023.[8]
References
- ^ "Details for: Vyalev". Health Canada. 5 February 2024. Retrieved 3 March 2024.
- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-06-23]". Health Canada. 23 June 2023. Retrieved 3 January 2024.
- ^ Rosebraugh, Matthew; Kym, Philip; Liu, Wei; Facheris, Maurizio; Benesh, Janet (9 April 2019). "A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson's Disease (P3.8-037)". Neurology. 92 (15 Supplement). doi:10.1212/WNL.92.15_supplement.P3.8-037. ISSN 0028-3878. S2CID 226858541.
- ^ Facheris, Maurizio; Criswell, Susan; Pavasia, Nirav; Pahwa, Rajesh; Locke, Charles; Robieson, Weining; Shprecher, David (14 April 2020). "Safety and Tolerability During a 4-Week Continuous Subcutaneous Infusion of ABBV-951, a New Drug Formulation for the Treatment of Parkinson's Disease: Final Results of a Phase 1b Study (1384)". Neurology. 94 (15 Supplement). ISSN 0028-3878.
- ^ Facheris, Maurizio; Benesh, Janet; Streit, Janet; Robieson, Weining; Zadikoff, Cindy; Standaert, David (14 April 2020). "Safety and Tolerability in Parkinson's Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study (4233)". Neurology. 94 (15 Supplement). ISSN 0028-3878.
- ^ Rosebraugh, Matthew; Kym, Philip; Liu, Wei; Facheris, Maurizio (14 April 2020). "ABBV-951 Maintains Stable Levodopa Exposure following Subcutaneous Infusion in Parkinson's Disease Patients (543)". Neurology. 94 (15 Supplement). doi:10.1212/WNL.94.15_supplement.543. ISSN 0028-3878. S2CID 266119262.
- ^ Facheris, Maurizio; Robieson, Weining; Fisseha, Nahome; Standaert, David (13 April 2021). "Efficacy and Safety of Foslevodopa/Foscarbidopa Versus Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients: Design of a Phase 3, Randomized, Double-Blind, Double-Dummy, Active Controlled 12-Week Trial (2251)". Neurology. 96 (15 Supplement). doi:10.1212/WNL.96.15_supplement.2251. ISSN 0028-3878. S2CID 266111372.
- ^ https://www.fiercepharma.com/pharma/abbvies-parkinsons-combo-drug-hits-wall-fda-questions-delivery-pump. Retrieved 25 November 2023.
{{cite news}}: Missing or empty|title=(help)